International Media Center (I.M.C) | International News & Health Desk
October 24, 2026
French health authorities have announced the world’s first documented human infection with Shamonda virus, involving a severely immunocompromised patient who died in early October. The case has drawn renewed attention to a virus that has been known to circulate among animals for more than six decades but had never previously been documented as causing human infection.
In an official statement issued on October 22, 2026, the French Ministry of Health confirmed that the infection was identified in a patient receiving treatment at Lyon University Hospitals (Hospices Civils de Lyon). Medical, laboratory, and epidemiological investigations remain underway to determine the circumstances of the infection and assess its potential implications for human health.
What Have Investigations Revealed?
According to Santé publique France, the country’s national public health agency, authorities were notified of the case on October 7, 2026, after specialized laboratory tests detected the virus in multiple biological samples collected from the patient.
The individual was severely immunocompromised and experienced serious neurological complications. Preliminary findings suggest that some of the patient’s neurological symptoms may have been associated with the Shamonda virus infection.
However, health officials have not established whether the virus directly caused the patient’s death or contributed to it, particularly given the patient’s complex underlying medical condition.
What Is Shamonda Virus?
Shamonda virus belongs to the genus Orthobunyavirus, within the family Peribunyaviridae. It is related to the Schmallenberg virus, which is known to infect certain ruminant animals.
The virus was first identified in 1965, when it was isolated from cattle in Nigeria. It was subsequently detected in several regions of Africa and Japan.
Shamonda virus primarily affects livestock, including cattle, sheep, and goats. In infected animals, it may be associated with symptoms such as fever, diarrhea, reduced milk production, reproductive disorders, and congenital abnormalities.
Spread of the Virus in Europe During 2026
The year 2026 has seen significant developments in the geographical distribution of Shamonda virus, following its first detection in animals in Europe.
Santé publique France reported the circulation of a new European strain, referred to as Shamonda-Europe, which was identified in several European countries during the summer.
As of October 20, 2026, the virus had been detected in cattle across 52 French administrative departments, with additional detections involving sheep and horses in other areas.
This spread among animals has prompted health authorities to strengthen surveillance and investigate the potential for transmission to humans.
How Might the Patient Have Contracted the Virus?
Preliminary investigations suggest that the infection may have been transmitted through the bite of a small blood-feeding insect belonging to the genus Culicoides, commonly known as biting midges.
These insects are recognized vectors of several animal viruses.
Authorities believe the infection may have occurred in eastern France, where viral activity among animals was detected during the spring and summer.
However, this transmission route has not been conclusively established. Investigations are continuing into the patient’s environmental exposures, travel history, and possible contact with infected insects or animals.
Can Shamonda Virus Spread Between Humans?
As of the publication of this report, there is no evidence demonstrating direct human-to-human transmission of Shamonda virus.
French health authorities and the European Centre for Disease Prevention and Control (ECDC) have indicated that the available information does not suggest a public health threat to the general population at this stage.
Nevertheless, the limited scientific data on human infections highlight the need for continued surveillance and research, particularly because the documented case involved a severely immunocompromised patient.
Are Treatments or Vaccines Available?
According to the World Health Organization (WHO), there are currently no specific antiviral treatments or vaccines developed for Shamonda virus.
Furthermore, a single documented human case does not provide sufficient evidence to establish the typical clinical symptoms, complication rates, or fatality risk associated with human infection.
Further clinical and laboratory research will be essential to better understand the virus’s behavior and its potential effects on human health.
International Monitoring and Ongoing Investigations
French authorities have notified the World Health Organization and the European Centre for Disease Prevention and Control of the case.
Investigations are continuing under the One Health approach, which recognizes the interconnected nature of human, animal, and environmental health.
Researchers are focusing on identifying possible transmission pathways, examining the epidemiological characteristics of the strain circulating in Europe, and strengthening laboratory capabilities to detect any potential additional human cases.
Ultimately, the documentation of the first human Shamonda virus infection does not indicate the emergence of a new epidemic. However, it represents a significant scientific development that warrants careful monitoring, particularly as researchers continue to investigate the nature of the infection and its potential impact on human health.
Reliable information from official public health authorities and peer-reviewed scientific research remains essential to understanding the actual risks, without unnecessary alarm or unsupported conclusions.
International Media Center (I.M.C)
Official Sources:
- French Ministry of Health, official statement dated October 22, 2026.
- Santé publique France (French Public Health Agency), scientific update dated October 23, 2026.
- World Health Organization (WHO).
- European Centre for Disease Prevention and Control (ECDC), assessment of the first human case.
